Immix Biopharma (IMMX) Other Non-Current Assets (2022 - 2026)

Immix Biopharma has disclosed Other Non-Current Assets across 5 years of filings, most recently posting $164723.0 for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $164723.0, up 706.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $164723.0 (up 706.75% YoY), and the FY2025 annual result was $93630.0, up 358.57% from the prior year.
• Other Non-Current Assets came in at $164723.0 for Q1 2026 at Immix Biopharma, up from $93630.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $175131.0 in Q1 2023 to a low of $6724.0 in Q4 2022.
• The 5-year median for Other Non-Current Assets is $38571.0 (2023), against an average of $65824.9.
• Across the five-year window, Other Non-Current Assets surged 1197.28% in 2023 and slumped 88.34% in 2024, its largest moves.
• Immix Biopharma's Other Non-Current Assets stood at $6724.0 in 2022, then soared by 1197.28% to $87229.0 in 2023, then tumbled by 76.59% to $20418.0 in 2024, then surged by 358.57% to $93630.0 in 2025, then jumped by 75.93% to $164723.0 in 2026.
• The last three Other Non-Current Assets figures came in at $164723.0 (Q1 2026), $93630.0 (Q4 2025), and $111689.0 (Q3 2025), per Business Quant data.